The contributions of lean tissue mass and fat mass to bone geometric adaptation at the femoral neck in Chinese overweight adults

2007 ◽  
Vol 34 (3) ◽  
pp. 344-353 ◽  
Author(s):  
Shan Wu ◽  
Shan Wu ◽  
Shu-Feng Lei ◽  
Shan Wu ◽  
Shu-Feng Lei ◽  
...  
Keyword(s):  
Femoral Neck ◽  
Fat Mass ◽  
Lean Tissue ◽  
Tissue Mass ◽  
Lean Tissue Mass ◽  
Overweight Adults

Lean Tissue Mass And Fat Mass Changes In HIV-infected Persons Following Moderate Intensity Exercise Training

2005 ◽  
Vol 37 (Supplement) ◽  
pp. S127
Author(s):  
Wesley D. Dudgeon ◽  
Kenneth D. Phillips ◽  
Stephanie E. Burgess ◽  
J. Larry Durstine ◽  
Gregory A. Hand
Keyword(s):  
Exercise Training ◽  
Fat Mass ◽  
Moderate Intensity ◽  
Moderate Intensity Exercise ◽  
Lean Tissue ◽  
Tissue Mass ◽  
Lean Tissue Mass

Effect of a soluble activin receptor type IIB on androgen-deprivation-induced effects on body composition

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 5133-5133
Author(s):  
J. Lachey ◽  
A. Koncarevic ◽  
J. Ucran ◽  
R. S. Pearsall ◽  
M. L. Sherman ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Body Composition ◽  
Side Effects ◽  
Fat Mass ◽  
Lean Mass ◽  
Receptor Type ◽  
Lean Tissue ◽  
Tissue Mass ◽  
Lean Tissue Mass ◽  
Adipose Mass

5133 Background: Androgen deprivation therapy (ADT) is a well-established treatment for hormone sensitive prostate cancer, but is associated with adverse side effects including loss of bone and lean mass and increased adipose mass. Activin receptor type IIB (ActRIIB) signaling is necessary for the negative regulation of lean tissue mass and treatment with a non-signaling, decoy ActRIIB results in a robust increase in lean tissue mass. Methods: Similar to ADT patients, orchiectomized (ORX) mice lose bone and lean mass and gain fat mass. To determine the therapeutic potential of inhibiting ActRIIB signaling to reduce the negative effects associated with ADT, we treated sham-operated (SHAM) and orchiectomized (ORX) mice with RAP-031, a fusion protein comprised of a form of the extracellular domain of ActRIIB linked to a murine Fc. Mice received twice weekly injections for 10 weeks with either vehicle (VEH) or 10 mg/kg RAP-031 (RAP). NMR scanning was used to determine body composition and whole body DEXA scans were performed to determine bone mineral density (BMD). Results: ORX resulted in a 4.4% decrease in BMD, an 18% reduction in lean tissue and a 41.6% increase in adiposity compared to the VEH-SHAM cohort. Both RAP-031treated groups of mice had significantly increased BMD and lean tissue mass and decreased adipose mass compared to their respective VEH groups. However, BMD, lean tissue and adiposity were not significantly different between the VEH-SHAM and RAP-ORX groups. These data illustrate that RAP-031 treatment completely attenuates ORX-induced alterations in bone, lean and fat mass. Conclusions: These data support the hypothesis that treatment with a form of soluble ActRIIB can offset negative side effects of ADT and have significant therapeutic implications for the treatment of patients with prostate cancer. [Table: see text] [Table: see text]

scholarly journals High baseline fat mass, but not lean tissue mass, is associated with high intensity low back pain and disability in community-based adults

2019 ◽  
Vol 21 (1) ◽  
Author(s):  
Sharmayne R. E. Brady ◽  
Donna M. Urquhart ◽  
Sultana Monira Hussain ◽  
Andrew Teichtahl ◽  
Yuanyuan Wang ◽  
...  
Keyword(s):  
Low Back Pain ◽  
Back Pain ◽  
Fat Mass ◽  
High Intensity ◽  
Low Back ◽  
Community Based ◽  
Lean Tissue ◽  
Tissue Mass ◽  
Lean Tissue Mass ◽  
High Baseline

scholarly journals Lean Tissue Mass And Fat Mass Changes In HIV-infected Persons Following Moderate Intensity Exercise Training

2005 ◽  
Vol 37 (Supplement) ◽  
pp. S127
Author(s):  
Wesley D. Dudgeon ◽  
Kenneth D. Phillips ◽  
Stephanie E. Burgess ◽  
J. Larry Durstine ◽  
Gregory A. Hand
Keyword(s):  
Exercise Training ◽  
Fat Mass ◽  
Moderate Intensity ◽  
Moderate Intensity Exercise ◽  
Lean Tissue ◽  
Tissue Mass ◽  
Lean Tissue Mass

The relative contributions of lean tissue mass and fat mass to bone density in young women

Bone ◽  
2005 ◽  
Vol 37 (4) ◽  
pp. 474-481 ◽  
Author(s):  
M.C. Wang ◽  
L.K. Bachrach ◽  
M. Van Loan ◽  
M. Hudes ◽  
K.M. Flegal ◽  
...  
Keyword(s):  
Bone Density ◽  
Young Women ◽  
Fat Mass ◽  
Lean Tissue ◽  
Tissue Mass ◽  
Lean Tissue Mass

Strategic creatine supplementation and resistance training in healthy older adults

2015 ◽  
Vol 40 (7) ◽  
pp. 689-694 ◽  
Author(s):  
Darren G. Candow ◽  
Emelie Vogt ◽  
Sarah Johannsmeyer ◽  
Scott C. Forbes ◽  
Jonathan P. Farthing
Keyword(s):  
Older Adults ◽  
Resistance Training ◽  
Muscle Strength ◽  
Fat Mass ◽  
Creatine Supplementation ◽  
Lean Tissue ◽  
Tissue Mass ◽  
Lean Tissue Mass ◽  
Leg Press ◽  
Repeated Measures Design

Creatine supplementation in close proximity to resistance training may be an important strategy for increasing muscle mass and strength; however, it is unknown whether creatine supplementation before or after resistance training is more effective for aging adults. Using a double-blind, repeated measures design, older adults (50–71 years) were randomized to 1 of 3 groups: creatine before (CR-B: n = 15; creatine (0.1 g/kg) immediately before resistance training and placebo (0.1 g/kg cornstarch maltodextrin) immediately after resistance training), creatine after (CR-A: n = 12; placebo immediately before resistance training and creatine immediately after resistance training), or placebo (PLA: n = 12; placebo immediately before and immediately after resistance training) for 32 weeks. Prior to and following the study, body composition (lean tissue, fat mass; dual-energy X-ray absorptiometry) and muscle strength (1-repetition maximum leg press and chest press) were assessed. There was an increase over time for lean tissue mass and muscle strength and a decrease in fat mass (p < 0.05). CR-A resulted in greater improvements in lean tissue mass (Δ 3.0 ± 1.9 kg) compared with PLA (Δ 0.5 ± 2.1 kg; p < 0.025). Creatine supplementation, independent of the timing of ingestion, increased muscle strength more than placebo (leg press: CR-B, Δ 36.6 ± 26.6 kg; CR-A, Δ 40.8 ± 38.4 kg; PLA, Δ 5.6 ± 35.1 kg; chest press: CR-B, Δ 15.2 ± 13.0 kg; CR-A, Δ 15.7 ± 12.5 kg; PLA, Δ 1.9 ± 14.7 kg; p < 0.025). Compared with resistance training alone, creatine supplementation improves muscle strength, with greater gains in lean tissue mass resulting from post-exercise creatine supplementation.

scholarly journals Meta-Analysis Examining the Importance of Creatine Ingestion Strategies on Lean Tissue Mass and Strength in Older Adults

Nutrients ◽  
2021 ◽  
Vol 13 (6) ◽  
pp. 1912
Author(s):  
Scott C. Forbes ◽  
Darren G. Candow ◽  
Sergej M. Ostojic ◽  
Michael D. Roberts ◽  
Philip D. Chilibeck
Keyword(s):  
Resistance Training ◽  
Meta Analysis ◽  
Creatine Supplementation ◽  
Strength Increase ◽  
Lean Tissue ◽  
Tissue Mass ◽  
Resistance Training Program ◽  
Lean Tissue Mass ◽  
Leg Press ◽  
Meta Analyses

Creatine supplementation in conjunction with resistance training (RT) augments gains in lean tissue mass and strength in aging adults; however, there is a large amount of heterogeneity between individual studies that may be related to creatine ingestion strategies. Therefore, the purpose of this review was to (1) perform updated meta-analyses comparing creatine vs. placebo (independent of dosage and frequency of ingestion) during a resistance training program on measures of lean tissue mass and strength, (2) perform meta-analyses examining the effects of different creatine dosing strategies (lower: ≤5 g/day and higher: >5 g/day), with and without a creatine-loading phase (≥20 g/day for 5–7 days), and (3) perform meta-analyses determining whether creatine supplementation only on resistance training days influences measures of lean tissue mass and strength. Overall, creatine (independent of dosing strategy) augments lean tissue mass and strength increase from RT vs. placebo. Subanalyses showed that creatine-loading followed by lower-dose creatine (≤5 g/day) increased chest press strength vs. placebo. Higher-dose creatine (>5 g/day), with and without a creatine-loading phase, produced significant gains in leg press strength vs. placebo. However, when studies involving a creatine-loading phase were excluded from the analyses, creatine had no greater effect on chest press or leg press strength vs. placebo. Finally, creatine supplementation only on resistance training days significantly increased measures of lean tissue mass and strength vs. placebo.

Abstract P330: Growth Differentiation Factor 15 Causes Cardiac Cachexia In Heart Failure

2021 ◽  
Vol 129 (Suppl_1) ◽  
Author(s):  
Da Young Lee ◽  
Zhe Jiao ◽  
Andrew Antolic ◽  
Daiana Weiss ◽  
M. Neale Weitzmann ◽  
...  
Keyword(s):  
Heart Failure ◽  
Food Intake ◽  
Cardiac Fibrosis ◽  
Lean Tissue ◽  
Tissue Mass ◽  
Lean Tissue Mass ◽  
Growth Differentiation Factor 15 ◽  
Tissue Weight ◽  
Reduced Fat ◽  
Differentiation Factor

Background: Cachexia is wasting of normal body tissue and occurs in chronic medical diseases. It is a common complication of heart failure (HF) that is associated with very high mortality. Growth differentiation factor 15 (GDF15) regulates food intake and can cause cancer cachexia. GDF15 is a sensitive biomarker in humans, though its biologic function in HF is unknown. This study investigated the role of GDF15 in HF. Methods: We utilized a genetic mouse model of dilated cardiomyopathy (DCM) caused by a mutation in the phospholamban gene (PLN R9C ). PLN R9C mice have dysregulated cardiac calcium handling (a common feature of nearly all forms of HF) and develop progressive DCM that leads to HF and premature death. Q-PCR and ELISA were performed to assess expression, tissue distribution and circulating levels of GDF15 in PLN R9C and age-matched wild type (WT) mice. A double transgenic mouse was created by crossing our DCM model with a constitutive Gdf15 knock-out (KO). Using this novel model, we quantified food intake, and assessed fat and lean tissue mass by tissue weight at necropsy and by dual-energy X-ray absorptiometry (DXA). Cardiac function was assessed using echocardiography, and histochemistry performed to quantify cardiac fibrosis. Survival was assessed by Kaplan-Meier. Results: GDF15 mRNA (43-fold; p<0.01) and protein (54-fold; p<0.01) were increased in LV tissue, and circulating GDF15 was elevated (8.3-fold; p=0.03) in PLN R9C mice. Gdf15 was expressed at low levels and was not increased in other organs in PLN R9C mice. PLN R9C mice developed cachexia (reduced fat and lean mass by tissue weight, reduced fat mass by DXA vs. WT; p<0.01 for all) and consumed less food (p<0.01 vs. WT). Gdf15 KO in PLN R9C preserved fat and lean tissue mass and resulted in higher food intake (p≤0.01 for all). Gdf15 KO had no effect on cardiac structure or function by echocardiography and PLN R9C / Gdf15 KO mice displayed only a small reduction in cardiac fibrosis relative to PLN R9C mice (3%; p<0.01). Despite this, Gdf15 KO prolonged survival in PLN R9C (29±3 vs. 25±3 weeks; p<0.01). Conclusions: GDF15 is a novel cardiac hormone produced in HF that triggers anorexia and cachexia in HF by an extra-cardiac mechanism.

Sign in / Sign up

Export Citation Format

Share Document